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Abstract
Background: Voxel-based algorithms using acute multiparametric-MRI data have been shown to accurately predict
tissue outcome after stroke. We explored the potential of MRI-based predictive algorithms to objectively assess the
effects of normobaric oxygen therapy (NBO), an investigational stroke treatment, using data from a pilot study of
NBO in acute stroke.
Methods: The pilot study of NBO enrolled 11 patients randomized to NBO administered for 8 hours, and 8 Control
patients who received room-air. Serial MRIs were obtained at admission, during gas therapy, post-therapy, and pre-
discharge. Diffusion/perfusion MRI data acquired at admission (pre-therapy) was used in generalized linear models
to predict the risk of lesion growth at subsequent time points for both treatment scenarios: NBO or Control.
Results: Lesion volume sizes ‘during NBO therapy’ predicted by Control-models were significantly larger (P = 0.007)
than those predicted by NBO models, suggesting that ischemic lesion growth is attenuated during NBO treatment.
No significant difference was found between the predicted lesion volumes at later time-points. NBO-treated
patients, despite showing larger lesion volumes on Control-models than NBO-models, tended to have reduced
lesion growth.
Conclusions: This study shows that NBO has therapeutic potential in acute ischemic stroke, and demonstrates the
feasibility of using MRI-based algorithms to evaluate novel treatments in early-phase clinical trials.
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Background
MRI voxel-based predictive algorithms based on admis-
sion MRI datasets including diffusion-weighted imaging
(DWI) and perfusion-weighted imaging (PWI), have
been shown to accurately predict tissue outcomes in
acute stroke patients [1,2] and animal stroke models
[3-6]. In the acute stroke setting, these models can be
used to predict the patient’s response to various treat-
ment options, enable better treatment selection, and
thereby improve patient outcome. Furthermore, MRI-
based algorithms have potential to be used in early-
phase clinical trials to assess the efficacy and toxicity of
investigational therapies by providing an estimate of tis-
sue likely to infarct without intervention, and comparing
this predicted outcome to the actual tissue status
observed post-treatment. Such algorithms have been
successfully used to demonstrate therapeutic efficacy of
recombinant tissue plasminogen activator (rt-PA) in ani-
mal [3] and human [7] studies. In these two studies, the
group given rt-PA had smaller actual lesion volumes
than was predicted using natural history models.
In this study, we extend our prior research by devel-
oping models under treatment and control conditions in
order to predict tissue outcome after normobaric oxygen
therapy (NBO), a promising investigational acute stroke
t r e a t m e n t[ 8 - 1 7 ] .W ea n a l y z e dd a t af r o map r o s p e c t i v e
randomized pilot study of normobaric oxygen therapy
(NBO) [18-20]. In the pilot study [18], NBO transiently
improved clinical deficits and reduced DWI lesions in
stroke patients with mismatches in lesion volumes on
DWI and PWI. These effects were most evident during
therapy, suggesting that NBO may slow down the
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strategy to extend the narrow time window for stroke
thrombolysis. In the present study we compared pre-
dicted tissue outcome on a voxel-wise basis under the
two treatment strategies, Room-air and NBO. We postu-
lated that differences between the expected outcomes of
these models will objectively validate prior observations
and provide insights into NBO’s mechanisms.
Methods
Patients
This study was approved by our Hospital’sH u m a n
Research Committee (approval number 2001P001176).
The NBO pilot study inclusion and exclusion criteria,
DWI and PWI imaging methods, and clinical and volu-
metric results have been published [18-20]. Data from
three additional randomized patients (2 treated with
NBO, one with room air), obtained after the original
report, were incorporated in this analysis. Briefly,
patients were eligible if they presented < 12 h after wit-
nessed stroke onset or < 15 h after last seen neurologi-
cally intact, and had a > 20% visually-estimated
mismatch in acute DWI and PWI lesion volumes. After
obtaining informed consent, patients were randomized
to room air (Control, n = 8) or NBO (high-flow oxygen
delivered via a facemask for 8 hours, n = 11). All
patients received MRIs upon admission (pre-treatment),
4 h later (during treatment), 24 h (post-treatment) and
before discharge. One patient from each group was
excluded due to hyperacute post-ischemic hemorrhage
[21]. Another Control patient was excluded due to ima-
ging artifacts. Reperfusion, defined as recanalization of a
previously occluded artery on MR-angiography (MRA)
or > 50% decrease in mean transit time (MTT) lesion
volume, was measured at 4 h and 24 h.
Image acquisition
DWI was acquired with b-value = 0 s/mm
2 and six dif-
fusion-weighted images with b-value = 1000 s/mm
2.
Apparent diffusion coefficient (ADC) maps were calcu-
lated as the negative slope of the linear regression fit of
the log DWI images versus their b-values. The isotropic
DWI map (iDWI) was calculated as the geometric mean
of the diffusion-weighted images. The b-value = 0 s/
mm
2 acquisition was used as the T2-weighted image
(T2WI). Non-uniformity correction was performed on
both the iDWI and the T2WI data sets [22]. PWI was
performed by acquiring dynamic susceptibility contrast-
weighted images during the first pass of a bolus of high-
magnetic susceptibility contrast agent. Cerebral blood
flow (CBF), cerebral blood volume (CBV), mean transit
time (MTT), and delay maps (Tmax) maps were calcu-
lated using local oscillation-index regularized singular
value decomposition with a block-circulant matrix [23]
for deconvolving concentration-time curves with an
automatically selected arterial input function [24].
GLM development
Details regarding the development of generalized linear
models (GLM) for predicting tissue infarction have been
published [7]. Briefly, tissue outcome is modeled as a
binary variable, with 1 representing lesioned tissue and
0 non-lesioned tissue. The probability of tissue lesion
development (P) can then be represented by the logistic
function, P=
1
1+e−η(x) (Equation 1), for which h(x) is a
linear function of its input parameters, η(x) = βTx + α
(Equation 2) and b is the vector of weighting coefficients
and a is the bias or intercept term for the GLM. For
this study, the input vector, x, consisted of the acute
T2W I ,A D C ,i D W I ,C B F ,C B V ,M T Ta n dT m a xm a p s .
All images were co-registered using semi-automated
image registration software to one another (FLIRT [25])
and to a probabilistic brain atlas [26] (MNI Autoreg
[27]), and then normalized with respect to mean values
measured in the normal contralateral white matter using
previously described techniques [7]. Training regions
consisted of tissue lesions delineated by a neuroradiolo-
gist as regions of hyperintensities on 4 h or 24 h DWIs
or before discharge MRIs (performed approximately 1-
week later), and non-lesions defined as remaining ipsi-
lateral hemisphere tissue not demonstrating artifacts on
admission MRI. Coefficients of the GLM were calculated
using an iterative re-weighted least squares algorithm (R
[28]) and then applied to admission MRI to produce
lesion risk maps for each patient. For all models, the
bootstrapped estimate [29] of the mean of the GLM
coefficients were used, with care taken that an equal
number of lesion and non-lesion samples were used for
each iteration to compensate for imbalanced training
data which can lead to models weighted towards pre-
dicting the majority class, i.e. non-lesion tissue [30].
Two sets of models were created to predict lesion
growth at each of the three subsequent time points: 4 h
(during treatment), 24 h (post-treatment) and Discharge.
Control-models were trained using all room-air treated
patients (n = 6). NBO-models were trained on oxygen-
treated patients (n = 10). Lesion risk maps for the NBO-
treated cohort were calculated using both types of mod-
els. To avoid bias from training and testing on the same
data, jack-knifing or leave-one-out approach was used to
evaluate the performance of the NBO-models [29]. The
coefficients for the models were tested for significance
and compared to one another (Z-tests).
Data analysis
All analyses were performed on co-registered datasets.
Manually outlined lesions at 4 h, 24 h and Discharge
Wu et al. Medical Gas Research 2012, 2:5
http://www.medicalgasresearch.com/content/2/1/5
Page 2 of 9were used to train the GLMs and to define the mea-
s u r e dl e s i o nv o l u m e(MLV) at each successive time
point. Lesion Change, defined as the ratio of the MLV
at each time point to the admission DWI lesion
volume, was compared between the NBO and control
groups (unpaired Student t-test). The predicted lesion
volume (PLV) was defined as tissue where GLM-pre-
dicted lesion risk was greater than a threshold of 50%.
A threshold of 50% was selected since the models were
designed to produce the optimal operating point at
this cutoff by using an equal number of lesion and
non-lesion voxels as part of the bootstrapped training.
PLV at each time point using each model (PLVControl
and PLVNBO) were calculated and compared. Regional
analysis was performed comparing T2W I ,A D C ,D W I ,
CBF, CBV, MTT and Tmax in areas where the PLV of
both models matched with areas where PLVControl
were greater than areas of PLVNBO. Correlations
between the two models were calculated (Pearson’s
product-moment) at each time point. Correlations
were also performed between ratios of PLVControl to
PLVNBO with respect to Lesion Change to predict the
expected responsiveness of individual patients to NBO.
Region of interest (ROI) analysis were performed in
tissue that was correctly predicted to become lesioned
(true positive, TP) by Control-models (TPControl)o r
NBO-models (TPNBO), in tissue that was falsely pre-
dicted to become lesioned (false positive, FP) using the
Control-model (FPControl)o rt h eN B O - m o d e l( F P NBO),
in tissue correctly predicted to not become a lesion
(true negative, TN) for Control-models (TNControl)o r
NBO-models (TNNBO), and in tissue incorrectly pre-
dicted to not become lesioned (false negative, FN) for
Control-models (FNControl) or NBO-models (FNNBO).
Mean predicted lesion risk in each region was calculated
and compared (ANOVA with post-hoc Tukey HSD test)
for each model. All statistical comparisons used one-
sided Wilcoxon-tests, unless otherwise noted. P < 0.05
was considered significant for all analyses, which were
limited to slices that had valid data for all co-registered
input image sets.
Results
Table 1 shows patient characteristics. Measured lesion
volumes were not significantly different between
groups at any time point. NBO-treated patients had
larger admission DWI lesion volumes and conse-
quently tended to have larger absolute lesion volumes
at all subsequent time points. An analysis of lesion
volume change from before (baseline) to during treat-
ment (4 h) showed significant reduction in DWI lesion
size in NBO-treated patients and an increase in Con-
trol patients, consistent with previous reports [18]. At
the other time points, lesion expansion was observed
in both groups, but to a lesser extent in the NBO-trea-
ted group.
Table 1 Clinical and imaging characteristics
Control-treated (n = 6) NBO-treated (n = 10)
Mean ± SD (Median) Mean ± SD (Median)
Age (y) 71 ± 18 (71) 67 ± 16 (70)
Female 4 (67%) 5 (50%)
Time Intervals
Symptom onset to admission MRI (h) 4.4 ± 2.0 (4.4) 7.3 ± 4.5 (5.9)
Admission-to-treatment MRI (h) 5.0 ± 1.4 (4.8) 4.3 ± 1.5 (3.9)
Admission-to-post-treatment MRI (h) 24.8 ± 1.9 (24.8) 24.4 ± 1.5 (24.2)
Admission-to-discharge MRI (d) 6.7 ± 1.9 (6.6) 6.0 ± 1.4 (5.8)
Acute NIHSSS 11 (9-12) 14 (9-18)
Reperfusion
Admission-to-treatment 1 (17%) 0
Treatment to post-treatment 0 5 (50%)
Measured Lesion Volume (cm
3)
Admission DWI 27 ± 44 (8) cm
3 37 ± 24 (30) cm
3
4 h DWI 28 ± 34 (15) cm
3 35 ± 25 (27) cm
3
24 h DWI 32 ± 39 (15) cm
3 49 ± 37 (43) cm
3
Discharge 41 ± 48 (23) cm
3 66 ± 42 (53) cm
3
Lesion Change (%)
4h* 153 ± 96 (134)% 90 ± 22 (90)%
24h 186 ± 142 (148)% 129 ± 29 (134)%
Discharge 223 ± 91 (203)% 192 ± 81 (178)%
*P = 0.036 Control-group vs NBO-group
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lesion development on a voxel-wise basis at 4 h, 24 h
and Discharge. The coefficients for the models using all
patient data in each respective cohort are shown in
Table 2. These coefficients represent the relative impor-
tance of each covariate on the likelihood of lesion devel-
opment. There were significant differences (P < 0.05)
between the coefficients as a function of treatment type
(i.e. NBO-model or Control-model) or time of lesion
development (i.e. 4 h, 24 h, or Discharge). The coeffi-
cients changed over time, with the iDWI coefficient hav-
ing less import for predicting outcome at later time-
points for both NBO- and Control-models.
Examples of predicted lesion development using the
two models for NBO-treated patients are shown in Fig-
ures 1 and 2, along with the voxel-wise differences.
Note the greatest differences between Control and NBO
models in the predicted risk of lesion development are
observed at 4 h.
As compared to lesion volumes predicted by NBO-
models, the Control-model predicted significantly larger
(P = 0.007) expected lesion volumes in the NBO-treated
group at 4 h (52 ± 30 vs. 46 ± 31 cm
3), but not at 24 h
(58 ± 33 vs. 59 ± 36 cm
3)o rD i s c h a r g e( 7 4±3 6v s .7 5
±3 8c m
3). The mean ± SD difference between PLVCon-
trol and PLVNBO for 4 h, 24 h, and Discharge were 5.3 ±
6.4, -1.0 ± 6.8, and -0.7 ± 5.7 cm
3. In regions where
PLVControl was greater than PLVNBO,T 2WI, ADC, DWI,
CBF, CBV and Tmax were significantly different (P <
0.05) from regions where PLVControl matched PLVNBO
for 4 h predictions. For the 24 h predictions, significant
differences (P < 0.05) were found for DWI, CBF, CBV,
and Tmax. For the Discharge predictions, significant dif-
ferences (P < 0.05) were found only for T2WI, DWI,
CBF, CBV, and Tmax. ADC, CBF, CBV and CBF were
more reduced, while T2WI, DWI and Tmax were higher
in the matched regions where both models predicted
lesion development compared to regions of discordance
between the models.
ROI analysis shows that lesion risk is greatest in TP
than in FP for both models at all time points (Figure
3A-C). Lesion risk in these regions is also shown to sig-
nificantly change over time.
For all time-points, the predicted lesion volumes were
significantly correlated with the measured (manually out-
lined) lesion volumes for both the Control-models (4 h: R
= 0.94 P < 0.0001; 24 h: R = 0.95 P < 0.0001; Discharge: R
= 0.88 P < 0.001) and the NBO-treatment models (4 h: R
= 0.97 P < 0.0001; 24 h: R = 0.97 P < 0.0001; Discharge: R
= 0.83 P < 0.01). Lesion Change at 4 h had a tendency to
be correlated with expected responsiveness to therapy, i.e.
the ratio of PLVControl/PLVNBO, (R = -0.61 P = 0.06), but
was poorly correlated at 24 h (R = -0.56 P = 0.09) and at
Discharge (R = 0.52 P = 0.12) (Figure 4). When DWI
lesions were observed to shrink rather than expand at the
4 h time point, PLVControl/PLVNBO was 121 ± 22%.
Discussion
In this study, we used objective methods to validate
prior observations showing the safety and efficacy of 8-
hour NBO in selected patients with acute ischemic
stroke. Further, we show that paired analysis of expected
outcomes under two therapeutic settings (control and
NBO) can be used to evaluate effects of novel therapeu-
tic interventions. Using multivariate voxel-based algo-
rithms, we can compare the expected outcome of each
voxel of tissue (were the natural cascade of ischemic
events to proceed unimpeded), versus their fate with
therapy. Despite the imbalanced number of subjects or
data in small pilot studies that occurs regardless of ran-
domization, as was true for this investigation and
reflected by the slightly larger DWI lesions in the NBO-
arm, we were still able to detect an alteration in the
patient’s lesion evolution from NBO-therapy.
Table 2 GLM Coefficients for the different models (Mean ± SD) for predicting lesion development
Models Bias T2WI ADC iDWI CBF CBV MTT Tmax
Models Predicting 4 h Lesion Development (during treatment)
Control -11 ± 1.4§ 4.0 ± 1.0§ -4.3 ± 1.3§ 9.3 ± 1.2§ -0.9 ± 0.2 0.7 ± 0.1 0.5 ± 0.2 0.07 ± 0.008§
NBO -17 ± 0.8§ 2.0 ± 0.3§ 0.10 ± 0.3*§ 11 ± 0.5§ -0.4 ± 0.2*§ -0.02 ± 0.2* 0.9 ± 0.2 0.05 ± 0.008§
Models Predicting 24 h Lesion Development (post-treatment)
Control -3.1 ± 1.0† 8.1 ± 0.8† -9.1 ± 1.0† 2.3 ± 0.8† -0.7 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.05 ± 0.007†
NBO -13 ± 0.5† 0.6 ± 0.2† 1.0 ± 0.2† 8.9 ± 0.3† 0.2 ± 0.09† -0.2 ± 0.08 1.3 ± 0.1 0.1 ± 0.006†
Models Predicting Discharge Lesion Development
Control -3.4 ± 0.6† 4.2 ± 0.4§ -5.1 ± 0.5§ 2.7 ± 0.5† -0.7 ± 0.1 0.5 ± 0.08 0.9 ± 0.1§† 0.06 ± 0.006
NBO -8.8 ± 0.3†§ 0.3 ± 0.1† 0.7 ± 0.2 6.1 ± 0.2†§ -0.2 ± 0.09*§ -0.06 ± 0.07* 0.9 ± 0.09§ 0.1 ± 0.006†
*P > 0.05 Non-significant coefficients
†P < 0.05 vs coefficients of 4 h models, §P < 0.05 vs coefficients of 24 h models
Coefficients for Control- and NBO-models were significantly different (P < 0.05) with the exception of T2WI, iDWI, CBF and Tmax for 4 h and MTT for 1-week time
points (displayed in light-gray).
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Page 4 of 9In our NBO pilot study [18], oxygen therapy transi-
ently improved clinical deficits and DWI lesion volumes
in stroke patients presenting with mismatches in lesion
volumes on DWI and PWI. This transient beneficial
effect of NBO has also been shown in rodent stroke stu-
dies [10-17]. Similarly in this study we found that DWI
Figure 1 Example 1 of Predicted Lesion Volume Development. (A) Admission MRI dataset for a 79 year-old woman with stroke who was
imaged 13 hours after she was last seen well and treated with NBO. (B) Corresponding GLM-predicted lesion risk maps (left panel) for Control
and NBO-models at each subsequent time point of imaging, and overlay map (right panel) of differences between the two models showing
ischemic tissue that is ‘potentially salvageable’ with NBO therapy. The GLM-predicted lesion volumes are asynthesis of data from the admission
MRI only. In this patient, the risk of tissue infarction in DWI/PWI mismatch regions was predicted to increase over time. For clarity, only GLM-
predicted lesion risk > 50% are shown overlaid on acute DWI. Note that the amounts of tissue predicted to infarct at all time-points with the
Control-models were greater than their NBO-model counterparts, with difference principally in the DWI/PWI mismatch region (arrowheads). In
the difference maps (B, right panel), the color scale represents infarction risk reduction as a result of NBO-therapy (conversely, larger values
represent greater likelihood of infarction if the patient was given Control-treatment).
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Page 5 of 9Figure 2 Example 2 of Predicted Lesion Volume Development. (A) Admission MRI dataset for a 64 year-old male patient imaged at 4.5
hours after stroke symptom onset who was treated with NBO. (B) Corresponding GLM-predicted lesion risk maps for Control and NBO-models
at each subsequent time point of imaging, and (C) Overlay map of differences between the two models showing ischemic tissue that is
‘potentially salvageable’ with NBO therapy. The GLM-predicted lesion volumes are a synthesis of data from the admission MRI only. In this
patient, the risk of tissue infarction in DWI/PWI mismatch regions was predicted to increase over time. For clarity, only GLM-predicted lesion risk
> 50% are shown overlaid on acute DWI. Note that the amounts of tissue predicted to infarct at all time-points with the Control-models were
greater than their NBO-model counterparts, with difference principally in the DWI/PWI mismatch region (arrowheads). In the difference maps (C),
the color scale represents infarction risk reduction as a result of NBO-therapy (conversely, larger values represent greater likelihood of infarction if
the patient was given Control-treatment).
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NBO-arm was reduced at 4 h compared to the Control-
arm. The current study extends these change-from-base-
line volumetric methods in individual modalities since
combining multiple imaging modalities have been
shown to more accurately predict tissue infarction than
any currently existing individual technique [1,2]. Predic-
tive modeling approaches also have the potential to test
whether a new therapy worsens tissue outcome. A theo-
retical concern with oxygen therapy is an increased risk
of generating toxic oxygen free radicals [31]. By showing
that the predicted lesion volumes assuming NBO-treat-
ment was not greater than those assuming room-air-
treatment, our objective data provides evidence that
NBO-therapy may not worsen tissue outcome at
Discharge.
In this study, we extend our previous GLM modeling
approach [1,7], which were limited to “natural history
models,” by developing tissue-signature models that use
pre-treatment data to predict expected tissue outcome if
a novel therapy was to be given. Our results showed
that during therapy FPControl was significantly higher
than FPNBO, suggesting NBO-treatment lowered the risk
of lesion development in these regions at 4 h. This effect
was not noted at the other time points. Further, we
found that greater mismatch between predicted outcome
using “natural history models” versus “NBO-treatment
model” was associated with smaller lesion expansion
and in some cases lesion reduction, suggesting these
models may be useful in selecting patients most likely to
benefit from NBO therapy. We speculate that risk maps
that synthesize multiparametric imaging, such as those
presented here and by others [2,32], may provide an
objective quantitative means for a priori predicting tis-
sue outcome on an individual voxel basis before therapy
administration. The algorithms proposed in this study
are thus initial steps towards developing tools that will
aid the clinician to tailor therapy on an individual
patient basis since these models can theoretically be
used to determine whether one therapy, e.g. NBO or rt-
PA, will produce smaller lesion volumes as compared to
Figure 3 GLM-predicted risk of lesion (mean ± SD) at (A) 4 h, (B) 24 h, and (C) Discharge in areas correctly predicted to lesion by the
Control-model (TPControl - white box) or by the NBO-model (TPNBO - gray box) and in areas incorrectly predicted to lesion by the
Control model (FPControl - white box) or the NBO-model (FPNBO - gray box). GLM-predicted lesion risk differed significantly (P < 0.05) among
the 4 regions for each of the models with the exception of FNControl and TNControl at Discharge. Differences between regions over time are also
shown: *P ≤ 0.01 4 h vs. 24 h. † P < 0.001 4 h vs Discharge. §P ≤ 0.001 24 h vs Discharge.
Figure 4 Scatter plot of Lesion Change vs expected
Responsiveness (ratio of PLVControl to PLVNBO) to therapy. For
the 4 h time point, large mismatches between the Control and NBO
models were found to be associated with lesion reduction.
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gists and stroke physicians who are faced with an
increasing myriad of imaging modalities [33] aimed at
interrogating the state of the ischemic tissue.
Insight into the mechanisms of tissue salvage by these
interventions may potentially be gleaned by comparing
the coefficients for the different models. For example,
we found that MTT plays a greater role in the NBO-
models than in Control-models in predicting which tis-
sue is likely to develop into a lesion at each of the time-
points. ADC and CBV appear to matter less in the NBO
during-treatment 4 h models, suggesting that with NBO,
t h ep r e s e n c ei nav o x e lo fl o wA D Ca n dl o wC B Va r e
less likely to result in lesion. This suggests that there
may be brief neuroprotection bestowed on at-risk tissue
by NBO despite lack of reperfusion (Table 1). In addi-
tion, we note that iDWI progressively assumes less
weight with Tmax playing a more important role over
time for the NBO-model and less importance for the
Control-model. We theorize that this is due to preserva-
tion of the DWI/PWI mismatch in the early stages of
lesion development by NBO therapy, with infarct expan-
sion into the area of abnormality delineated by Tmax
maps, which have been speculated to be a reflection of
the extent of collateral flow and hence tissue salvage
[23,34,35]. We also observed greater variability in NBO-
models than in the Control-models. We speculate that
this is in part due to greater heterogeneity in patient
response to NBO therapy, which are likely mediated by
several clinical factors that cannot be captured in neu-
roimaging, such as age, gender, blood pressure, blood
glucose levels, or hematocrit, which have been shown to
effect rates of recanalization and hemorrhagic transfor-
mation after intravenous or intra-arterial thrombolysis
[36]. Although randomization will somewhat compen-
sate for these differences, it may be necessary to expli-
citly incorporate non-imaging covariates in MRI-based
multivariate algorithms in order to improve prediction
of tissue outcome in patients given novel intervention.
Tissue-based models have some limitations. For exam-
ple, the accuracy of predictions depends on the training
data [7]. For these models to be applicable to a general
stroke population, one would need both larger training
data sets and more sophisticated models that incorpo-
rate factors that mediate lesion evolution. The imbal-
ance in the rate of reperfusion in our Control group
( 1 7 % )c o m p a r e dt oN B Og r o u p( 5 0 % )c o u l dp a r t l y
explain the differences observed between the model per-
formances. We have shown previously that models pre-
dicting outcome of patients after thrombolysis who
experience early reperfusion perform poorly, probably
due to salvage of tissue that would have otherwise
infarcted [7]. Likewise, NBO-therapy may play an indir-
ect role in reperfusion, as evidenced by reports of
increased cerebral blood flow and blood volume during
NBO in peri-infarct regions [15-17]. However, future
studies predicting outcome in dichotomized analyses
between patients who reperfuse and those who do not
in both groups should be performed to better discrimi-
nate the effects of reperfusion on NBO-treated patients.
Another important issue before these models can be
used in a clinical decision-making setting is reproduci-
bility of model parameters across centers. For example,
the coefficients for the Discharge Control-model may
differ significantly between studies [7] due to factors
such as different onset-to-MRI times, patient inclusion
criteria, patient populations, and PWI techniques.
Conclusion
Our findings indicate that predictive algorithms can be
used to estimate risk of lesion development for patients
given therapeutic interventions such as NBO. Differ-
ences between predicted results for control models and
treatment models were found on a volumetric basis (i.e.
predicted lesion volume) as well as on a voxel-wise basis
(i.e. probability of lesion development) suggesting a ther-
apeutic benefit for NBO at 4 h. Further studies are
needed to determine the utility of MRI predictive algo-
rithms in stroke clinical trials, and to confirm the safety
and efficacy of NBO in acute ischemic stroke.
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